Search Results

From left: Amylyx Co-founders and Co-CEOs Justin K

Deals

Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

While supportive of Amylyx’s acquisition of a GLP-1 drug, analysts say the company’s future hinges on key upcoming readouts from multiple products in its pipeline.

July 24, 2024

·

5 min read

·

Heather McKenzie

Genetown

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Conference.

May 8, 2024

·

1 min read

Pictured: Amylyx co-CEOs Josh Cohen and Justin Klee

Mergers & Acquisitions

Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger

After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals is looking to target the GLP-1 space with the purchase of Eiger BioPharmaceuticals’ avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia.

July 10, 2024

·

2 min read

·

Tyler Patchen

Business

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Amylyx Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.

May 9, 2024

·

18 min read

Genetown

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference.

June 4, 2024

·

1 min read

Business

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024.

May 2, 2024

·

1 min read

Drug Development

Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages

Amylyx looks to the future after Relyvrio withdrawal, ADCs continue to attract investment and the drug shortage persists in the U.S.

April 16, 2024

·

1 min read

·

Greg Slabodkin, Heather McKenzie, Tyler Patchen

Drug Development

Future of Amylyx’s ALS Drug in Question After Phase III Failure

Friday’s topline data from the Phase III PHOENIX trial of Relyvrio, which won approval in 2022, showed no significant difference on either the primary or secondary endpoints, according to Amylyx.

March 8, 2024

·

3 min read

·

Heather McKenzie

Genetown

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management.

April 8, 2024

·

3 min read

Pictured: 3D illustration of a DNA double-helix

Drug Development

Amylyx Plots New Path in Rare Genetic Disease After Relyvrio Withdrawal

On the heels of withdrawing Relyvrio from the U.S. and Canadian markets, Amylyx is now charting a path in Wolfram syndrome with promising interim Phase II data for its lead asset AMX0035.

April 11, 2024

·

2 min read

·

Tristan Manalac